Free tools, free alerts. Create a free account to get sector-matched alerts and save your searches.
Create free account →
NAFDAC has intensified its regulatory oversight with new alerts on counterfeit drugs, blacklisting of non-compliant manufacturers, and guidance on medical device investigations. These actions signal a stricter enforcement environment, particularly for pharmaceutical and medical device companies, requiring enhanced compliance and vigilance. Businesses should review their supply chains and reporting procedures to avoid penalties and protect public health.
Pharmaceuticals
Medical Devices
Food and Beverages
Import/Export
Healthcare
NAFDAC joins the Federal Ministry of Health and Social Welfare, nutrition partners, and the global community in celebrating World Breastfeeding Week 2026
NAFDAC
NAFDAC celebrates World Breastfeeding Week, promoting breastfeeding as a public health priority.
May lead to increased awareness and potential regulations supporting breastfeeding-friendly practices in workplaces and public spaces.
Handling Manufacturer Investigation Reports for Medical Devices and IVDs
NAFDAC
NAFDAC provides guidance on handling Manufacturer Investigation Reports (MIRs) for medical devices and IVDs to ensure timely and effective response to quality issues.
Medical device and IVD companies must establish robust procedures for investigating and reporting complaints, adverse events, and quality issues to NAFDAC.
Blacklisting of Onifam Laboratories Ltd
NAFDAC
NAFDAC blacklists Onifam Laboratories Ltd and associated entities from pharmaceutical business activities due to regulatory misrepresentation and improper use of approvals.
Pharmaceutical companies must ensure strict compliance with NAFDAC regulations to avoid blacklisting, which can severely disrupt business operations.
Public Alert No. 037/2026 – Alert on Suspected Counterfeit Pulmicort® (Budesonide) Inhalation Suspension
NAFDAC
NAFDAC alerts the public to suspected counterfeit Pulmicort® (Budesonide) inhalation suspension in the market.
Pharmacies and distributors must verify product authenticity and report any suspicious products to NAFDAC to prevent distribution of counterfeit drugs.
Public Alert No. 036/2026 – Alert on Suspected Counterfeit Products Mimicking Forxiga® (Dapagliflozin)
NAFDAC
NAFDAC alerts the public to suspected counterfeit Forxiga® (Dapagliflozin) products in the market.
Healthcare providers and patients should be vigilant about counterfeit diabetes medication; businesses should enhance supply chain integrity.
SON rides on e-platform to facilitate international trade - Business News Nigeria
Other
SON is using an e-platform to streamline international trade processes.
Businesses involved in import/export may benefit from faster and more transparent procedures with SON.
How to Register Your Fish Farm with NEPC Nigeria: A Complete Export Guide - within nigeria
Other
A guide on registering fish farms with NEPC for export purposes.
Fish farmers and exporters should follow NEPC registration requirements to access export markets and comply with regulations.
Increased enforcement against counterfeit drugs and non-compliant manufacturers.
Emphasis on robust pharmacovigilance and medical device reporting.
Potential for stricter import/export documentation and e-platform adoption.
Opportunities for compliance-focused businesses to gain market trust.
Need for enhanced supply chain verification to avoid counterfeit products.
1
Review and strengthen internal quality assurance and reporting procedures for medical devices and pharmaceuticals.
2
Verify the authenticity of all pharmaceutical products in stock and report any suspected counterfeits to NAFDAC.
3
Ensure all regulatory approvals and certificates are up-to-date and properly used to avoid blacklisting.
4
Stay informed on NAFDAC alerts and guidelines, and implement necessary changes promptly.
5
For importers/exporters, utilize SON's e-platform and ensure compliance with NEPC registration for agricultural exports.